{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"2.6","value":"1.6"},{"groupId":"OG001","lowerLimit":"1.1","upperLimit":"1.4","value":"1.2"},{"groupId":"OG002","lowerLimit":"3.0","upperLimit":"9.8","value":"5.2"},{"groupId":"OG003","lowerLimit":"1.4","upperLimit":"2.9","value":"2.6"},{"comment":"Insufficient data to calculate upper limit of confidence interval","groupId":"OG004","lowerLimit":"1.1","upperLimit":"NA","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"Progression-free survival according to iRECIST was defined as the time from the first day of study treatment to the first date of radiological disease progression according to iRECIST or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle as a once-daily dose.","id":"OG000","title":"Part A (Nanrilkefusp Alfa Monotherapy)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle twice a day as 2 divided doses (50%:50%) with the second dose on each treatment day administered 8 hours (±15 min) after the first dose.","id":"OG001","title":"Part A1 (Nanrilkefusp Alfa Divided Dosing, Monotherapy)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle as a once-daily dose.\n\nPembrolizumab 200 mg was administered intravenously on day 1 of the 21-day treatment cycle.","id":"OG002","title":"Part B (Nanrilkefusp Alfa Combined With Pembrolizumab)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle as a once-daily dose.","id":"OG003","title":"Part D (Nanrilkefusp Alfa Monotherapy, Expansion at the RP2D Identified in Part A)"},{"description":"Nanrilkefusp alfa was administered on day 1 (±1 day), day 2, day 8, and day 9 of the 21-day treatment cycle twice a day as 2 divided doses (50%:50%) with the second dose on each treatment day administered 8 hours (±15 min) after the first dose. Pembrolizumab 200 mg was administered intravenously on day 1 of the 21-day treatment cycle.","id":"OG004","title":"Part B1 (Nanrilkefusp Alfa Twice Daily With Pembrolizumab, Expansion at RP2D Identified in Part A)"}],"paramType":"MEDIAN","populationDescription":"In the trial protocol and SAP it was pre-specified that the arms in individual trial parts will be analyzed combined (A, A1, B, D, and B1).","reportingStatus":"POSTED","timeFrame":"Day 1 up to approximately 5 years 5 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}